Refine by
Applications
- Solutions for Endometriosis
- Solutions for Severe but Non-Specific Symptoms
- Microbiome Therapeutics for Clinical Trials
- Pipeline for Infectious Diseases
- Pipeline for Immuno-Oncology
- Pipeline for Precision Medicine
- Affilin - Precision Targeting Technology for Protein Drug Conjugates
- Affilin - Precision Targeting Technology for Radio Conjugates
- Affilin - Precision Targeting Technology for Cellular Therapies
- Affilin - Precision Targeting Technology for Multispecific Ligands
Drug Candidate Equipment & Supplies
120 equipment items found
Manufactured by:Gesynta Pharma AB based inStockholm, SWEDEN
Gesynta Pharma’s drug candidate GS-073 is expected to enter clinical phase I in 2022. It is currently in the final stages of preclinical development. This project will be addressing an indication with high unmet need, which is separate from systemic ...
Manufactured by:Gesynta Pharma AB based inStockholm, SWEDEN
The drug candidate GS-659, which is sprung from Gesynta Pharma’s drug development platform, is currently in preclinical development phase. Project updates will be announced in due ...
Manufactured by:Gesynta Pharma AB based inStockholm, SWEDEN
GS-248 is Gesynta Pharma’s most advanced drug candidate, currently in clinical development as a potential treatment of systemic sclerosis. Recent clinical phase I data in healthy individuals show that GS-248 potently inhibits the production of PGE2 in a tolerable and safe manner, while increasing the observed levels of protective and vasodilatory ...
by:Oncodesign based inDijon, FRANCE
Select the best drug candidates and their biomarkers using our expertise in pharmacology! The PREDICT® technology module is a centralized manifestation of the key scientific competence of our Experimentation activity. This module is the result of more than 20 years of investment and experience that are the cornerstone of Oncodesign’s international ...
Manufactured by:JD Bioscience Inc. (JDB) based inBuk-gu, SOUTH KOREA
JDB is developing a novel drug candidate for heart disease that can rescue heart function at a cellular level, and can eventually help improving heart ...
Manufactured by:JD Bioscience Inc. (JDB) based inBuk-gu, SOUTH KOREA
JDB is developing a novel drug candidate for acute pancreatitis that can effectively reduce inflammation of the pancreas by modulating mitochondrial functions in pancreatic ...
Manufactured by:Addex Therapeutics based inGeneva, SWITZERLAND
Our partner, Indivior, has licensed worldwide rights to our GABAB PAM program and is responsible for all development, manufacture and commercialization of any selected GABAB PAM drug candidates. Under the agreement, we are responsible for executing a research program funded by Indivior to discover novel drug candidates. Indivior ...
Manufactured by:Addex Therapeutics based inGeneva, SWITZERLAND
Our license agreement with Indivior provides for a funded research program, under which we have the right to select drug candidates for exclusive development in certain indications outside of SUD. We plan to develop our selected drug candidates in CMT1a, chronic cough and pain. These indications have been validated with baclofen, ...
Manufactured by:Confo Therapeutics based inGhent/Zwijnaarde, BELGIUM
Confo Therapeutics is building a pipeline of drug candidates with the potential to transform therapeutic outcomes for patients with severe illnesses lacking disease-modifying ...
by:Ainovo Biotech Inc. based inSacramento, CALIFORNIA (USA)
AlOptimus™ brings to bear AINovo's proprietary machine learning algorithms on our highly curated datasets to enhance the therapeutic profiles of drug candidates. The AlOptimus platform optimizes validated candidates to derisk development and inform clinical ...
Manufactured by:CytomX Therapeutics, Inc. based inSouth San Francisco, CALIFORNIA (USA)
CytomX and Amgen are developing CX-904, a T-cell engaging bispecific Probody candidate against Epidermal Growth Factor Receptor (EGFR) and CD3. The drug candidate is advancing towards IND-enabling studies. CytomX is responsible for the IND filing, targeted for late 2021, and for early clinical development with Amgen leading later stage ...
Manufactured by:BioArctic AB based inStockholm, SWEDEN
The drug candidate ABBV-0805 is a monoclonal antibody that selectively binds and eliminates oligomers and protofibrils of alpha-synuclein. The goal is to develop a disease modifying treatment that stops or slows down disease ...
Manufactured by:Krieger AG based inMuttenz, SWITZERLAND
Dissolution of expensive shear sensitive API's, proteins, Developing and processing small molecule and complex biologic drug candidates. Or just vacuum ...
Manufactured by:3B Pharmaceuticals GmbH based inBerlin, GERMANY
Discovery and preclinical development of peptide drug candidates have been 3BP’s core competencies since the company’s inception. ...
by:STALICLA based inGeneve, SWITZERLAND
DDU validates ASD phenotype groups and drug candidates through observational studies and investigational trials. DDU combines expertise in operations, medicine, drug and clinical development, to bring STALICLA’s clinical-stage treatment options closer to ...
Manufactured by:Regeneron Pharmaceuticals Inc. based inTarrytown, NEW YORK (USA)
VelocImmune is our unique technology for producing fully human monoclonal antibodies. VelocImmune creates a multitude of optimized antibody drug candidates efficiently and directly from immunized mice. This approach overcomes the limitations of traditional platforms by rapidly creating fully human antibodies that tightly bind to therapeutic targets and avoid ...
by:Enveric Biosciences, Inc. based inNaples, FLORIDA (USA)
It streamlines pharmaceutical design by predicting ideal binding structures of molecules, manufacturing capabilities and pharmacological effects to help determine ideal drug candidates, tailored to each indication. Each of these patentable molecules is further screened to see how changes to its makeup alter its effects and whether the new molecule might be used ...
Manufactured by:GENFIT based inLoos, FRANCE
We are conducting a research program to develop an anti-fibrotic drug candidate, with a priority given to liver fibrosis. This program consists in a repositioning of Nitazoxanide, or NTZ*, that is being investigated for the treatment of fibrosis in pre-clinical disease models. NTZ is currently being evaluated in an investigator-initiated proof-of-concept ...
Manufactured by:Jericho Sciences, LLC based inDurham (RTP), NORTH CAROLINA (USA)
Jericho is developing a new therapeutic drug for FIV infection in cats, working toward a New Animal Drug Application (NADA) with the FDA. Our ongoing studies indicate that Jericho’s small molecule drug candidate can reduce FIV virus levels in chronically-infected cats for many months in the absence of continuing treatment. ...
Manufactured by:Eupraxia Pharmaceuticals based inVictoria, BRITISH COLUMBIA (CANADA)
Our patented technology is designed to be tailored to a wide variety of drugs and therapeutic indications. In addition to our lead drug candidate (EP-104IAR), Eupraxia is currently developing an extended-release post-surgical anesthetic (EP-105) and antibiotic (EP-201). Eupraxia hopes to add 1-2 additional candidates to our ...